Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 21,040 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
Interventions: GS-9901; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 6
States / cities: Duarte, California • Fresno, California • Whittier, California + 3 more

Conditions: Menopause
Interventions: Placebo, S-equol; Drug
Lead sponsor: Ausio Pharmaceuticals, LLC; Industry
Eligibility: Female only
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Louisville, Kentucky • Cincinnati, Ohio • Cleveland, Ohio + 2 more

Conditions: Pregnancy, High Risk, Type 1 Diabetes
Interventions: Insulin, DEXCOM Continuous Glucose Monitor; Drug · Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Head and Neck Neoplasm, Malignant Head and Neck Neoplasm
Interventions: Computed Tomography Perfusion Imaging; Radiation
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pain, Postoperative, Postoperative Pain, Acute
Interventions: Acetaminophen, Celecoxib, Gabapentin; Drug
Lead sponsor: Northwell Health; Other
Eligibility: Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Bay Shore, New York

Conditions: Contraception
Interventions: AG200-15, Levora; Drug
Lead sponsor: Agile Therapeutics; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: Mobile, Alabama • Green Valley, Arizona • Tucson, Arizona + 16 more

Conditions: Alopecia
Interventions: Platelet Rich Plasma system; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Arthralgia, Obesity
Interventions: anastrozole, letrozole, exemestane, Tamoxifen; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Homozygous Familial Hypercholesterolemia (HoFH)
Interventions: Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy; Drug
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 4
States / cities: Columbus, Ohio • Portland, Oregon • Philadelphia, Pennsylvania + 1 more

Conditions: Weight Gain
Interventions: Peanut snacks, No peanut-containing snacks; Other
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: Opioid-use Disorder
Interventions: Reminders messages to improve adherence.; Behavioral
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Niacin, fenofibrate, placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Colon Cancer
Interventions: Screening Colonoscopy; Other
Lead sponsor: Mike O'Callaghan Military Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Glaucoma, Ocular Hypertension
Interventions: bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Artesia, California

Conditions: Functional Abdominal Pain, Functional Dyspepsia, Irritable Bowel Syndrome, Functional Gastrointestinal Disorders
Interventions: Placebo Suspension, Hyoscyamine; Other · Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 8 Years to 21 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
Interventions: CD7.CAR/28zeta T Cells; Genetic
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2043
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Diabetic Foot Ulcer
Interventions: Exercise; Behavioral
Lead sponsor: Mercer University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Sarcoma,Soft Tissue
Interventions: 2% intranasal mupirocin ointment, 4% chlorhexidine gluconate body cleanser; Drug
Lead sponsor: Adam Olson; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: CNS Malignancy
Interventions: FDG Positron Emission Tomography, Chemical Exchange Saturation Transfer Magnetic Resonance Imaging; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Opioid Use, Chronic Pain
Interventions: Yoga classes; Behavioral
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Medication Adherence, Heart Failure, Aging
Interventions: SystemCHANGE; Behavioral
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 50 Years and older
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Belleville, Illinois

Conditions: Emotional Adjustment
Interventions: Musical Contour Regulation Facilitation (MCRF); Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 3 Years to 5 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Coconut Grove, Florida

Conditions: Solid Tumors
Interventions: bevacizumab, everolimus, panitumumab; Drug
Lead sponsor: Herbert Hurwitz, MD; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Human Immunodeficiency Virus
Interventions: Ad26.Mos4.HIV, MVA-Mosaic, Clade C gp140 + Mosaic gp140, Placebo; Biological · Drug
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma

Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients

Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)

Whole-Neck Computed Tomography Perfusion Scan in Imaging Patients With Head and Neck Tumors

Impact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries

Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm

A Study of PRP Treatment for Hair Loss After Cancer Therapy in Women With Breast Cancer

Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer

A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501

Role of Peanuts in Healthy Weight Gain in Athletic Individuals

Mobile Medication Adherence Platform for Buprenorphine-Naloxone During Treatment of Opioid Use Disorder: Phase I Study

Obesity and Nonalcoholic Fatty Liver Disease

Vitamin D and Screening Colonoscopy or Polyp Surveillance

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Efficacy of Open Label Placebo in Children With FGIDs

Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells

The Effect of Exercise on Wound Healing While Off-loading

Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO)

A Study of Metabolic Agents Following Brain Radiation

Optimization and Multi-Site Feasibility of Yoga for Chronic Pain in People in YOGAMAT-II - Phase I

SystemCHANGE™ Intervention on Medication Adherence in Older Adults With Heart Failure

MCRF Clinical Pilot Study

BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment